MBX Biosciences Raises Cash Runway to $460M and Plans Q2 Phase II Update
MBX Biosciences ended 2025 with $373M cash and completed an $87M ATM sale, extending its cash runway to $460M through 2029. The company anticipates one-year phase II hypoparathyroidism data in Q2 2026 and a global registrational phase III start for once-weekly PTH therapy in Q3.
1. Cash Position and Runway
MBX ended 2025 with $373M in cash and completed an $87M ATM sale, extending its cash runway to $460M through 2029. Management highlighted that this funding will support phase III development of canvuparatide and associated precommercial activities.
2. Hypoparathyroidism Program
Canvuparatide, MBX’s once-weekly parathyroid hormone replacement therapy, is approaching an end-of-phase II FDA meeting this quarter. The company expects one-year open-label extension data in Q2 2026 and plans to initiate a global registrational phase III study in Q3 alongside commercialization planning.
3. Obesity Pipeline
MBX-4291, a once-monthly GLP-1/GIP co-agonist, is in a three-part phase I program including SAD, MAD and a 12-week regimen transitioning to monthly dosing. A key 12-week data readout is expected in Q4 2026 to support monthly dosing claims and tolerability.
4. Discovery and Preclinical Efforts
Beyond clinical-stage assets, MBX is advancing discovery programs targeting amylin and glucagon receptors, exploring triple-agonist approaches and other preclinical candidates to expand its obesity and metabolic disease portfolio.